



Divi's Laboratories Limited

Date. 31st October 2017

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

**Sub: Un-audited financial results for the quarter and half-year ended
30th September 2017 and limited review report –reg**
**Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements), Regulations, 2015**

Further to our letter dated 20th October, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Tuesday, 31st October 2017 has approved Un-audited Financial Results for the quarter and half-year ended 30th September, 2017.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the quarter and half-year ended 30th September 2017.
2. Limited Review Report on the Standalone Financial Results
3. Press Release on the Financial Results of the Company

The Board meeting commenced at 15:30 Hrs and concluded at 18:30 Hrs

This is for your information and records.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2017

(₹. in Lakhs)							
	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	89020	82120	100543	171140	202262	406577
2	Other Income	3359	2968	2027	6327	3658	7598
3	Total Revenue from Operations (1+2)	92379	85088	102570	177467	205920	414175
4	Expenses						
	a) Cost of materials consumed	31352	32152	41038	63504	78153	156319
	b) Purchases of stock-in-trade	0	0	0	0	0	0
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4378	1007	(2564)	5385	(1160)	(2161)
	d) Employee benefits expense	10482	10070	17964	20552	28083	49031
	e) Depreciation and amortization expense	3393	3231	3075	6624	6087	12326
	f) Finance Costs	75	49	39	124	77	225
	g) Other Expenses	15088	14409	14984	29497	27690	59612
	Total expenses	64768	60918	74536	125686	138930	275352
5	Profit before exceptional Items and tax (3-4)	27611	24170	28034	51781	66990	138823
6	Exceptional items	0	0	0	0	0	0
7	Profit before Tax (5-6)	27611	24170	28034	51781	66990	138823
8	Tax Expense						
	a) Current Tax	5544	4827	5759	10371	13833	28523
	b) Deferred Tax	1389	1689	(110)	3078	591	4973
	Total Tax Expense	6933	6516	5649	13449	14424	33496
9	Net Profit for the period (7-8)	20678	17654	22385	38332	52566	105327
10	Other Comprehensive Income: Items that will not be reclassified to Profit or Loss: - Remeasurement of post-employment benefit obligation (net of tax)	(38)	(36)	(65)	(74)	(130)	(140)
11	Total comprehensive Income for the period (9+10)	20640	17618	22320	38258	52436	105187
12	Paid-up Equity Share Capital (Face Value: ₹.2 per share)	5309	5309	5309	5309	5309	5309
13	Other Equity						535582
14	Earnings per Share (of ₹. 2/- each) (not annualized)						
	a) Basic	7.79	6.65	8.43	14.44	19.80	39.68
	b) Diluted	7.79	6.65	8.43	14.44	19.80	39.68



Standalone Statement of Assets and Liabilities:

(₹. in Lakhs)

S.No.	Particulars	As At	
		30.09.2017	31.03.2017
		Unaudited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	165011	155570
	Capital work-in-progress	44900	44357
	Intangible assets	364	325
	Financial assets		
	a) Investments	837	837
	b) Loans	1672	1856
	c) Other financial assets	3846	3846
	d) Other non-current assets	8958	10305
	Sub-total: Non-current assets	225588	217096
2	Current assets		
	Inventories	114190	125576
	Financial assets		
	a) Investments	162124	163072
	b) Trade receivables	90859	100289
	c) Cash and cash equivalents	451	855
	d) Bank balances other than c) above	20590	5792
	e) Loans	440	553
	f) Other financial assets	1918	1493
	g) Other current assets	9218	6282
	Sub-total: Current assets	399790	403912
	TOTAL ASSETS	625378	621008
B	EQUITY AND LIABILITIES		
1	Equity:		
	Share Capital	5309	5309
	Other Equity		
	a) Reserves and Surplus	541890	535582
	Sub-total: Shareholders' funds	547199	540891
2	Liabilities:		
	Non-current liabilities		
	Financial liabilities		
	a) Borrowings		
	b) Provisions	1730	1530
	c) Deferred tax liabilities (net)	16081	13003
	Sub-total: Non-current liabilities	17811	14533
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	5152	3574
	b) Trade payables	22883	38156
	c) Other financial liabilities	28320	19796
	d) Other current liabilities	3685	3930
	e) Provisions	328	128
	Sub-total: Current liabilities	60368	65584
	Total Liabilities	78179	80117
	TOTAL EQUITY AND LIABILITIES	625378	621008



NOTES:

1. The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 31st October, 2017.
2. Results for the quarter ended 30th September 2017 were subjected to 'limited review' by the Auditors and their report contains no qualification.
3. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
4. The format for un-audited quarterly results as prescribed in SEBI's Circular No.CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016, Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
5. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
6. The company's Unit-II at Visakhapatnam, Andhra Pradesh was inspected by HPRA (Ireland) and JAZMP (Slovenia) from 31st July, 2017 to 4th August, 2017 and the inspection concluded successfully with no critical observations.
7. The company's Unit-II has also been inspected by the US-FDA from 11th September 2017 to 19th September 2017. This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations of Nov-Dec, 2016. All the previous observations have been confirmed as completed and resolved. On completion of the current inspection, the Investigators of US-FDA have issued a Form-483 with 6 observations and the company filed its response to the same within the stipulated time.
8. Revenue for the corresponding previous quarters ended 30th June, 2017 and 30th September, 2016, the half-year ended 30th September, 2016 and the year ended 31st March, 2017 were reported inclusive of Excise Duty. The Government of India has implemented Goods and Services Tax (GST) effective 1st July, 2017 replacing excise duty, service tax and other indirect taxes. Accordingly, as per Ind AS 18, Revenue for the quarter ended 30th September, 2017 is reported net of GST. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹. in Lakhs)

	Quarter ended			Half Year ended		Year ended
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
Revenue from operations (net of excise duty)	88752	81263	99418	170015	200226	402386

9. As approved by the Members of the company at the 27th Annual General Meeting held on 25th September, 2017, the company has disbursed on 10th October, 2017 a dividend of ₹. 10 per equity share of ₹. 2 each for the year ended 31st March, 2017, aggregating to ₹. 26547 lakhs.
10. Details of forex gain/(loss) are given below:

(₹. in Lakhs)

	Quarter ended			Half Year ended		Year ended
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
Forex gain/(loss)	1059	701	(1144)	1760	(1071)	(3910)

11. Figures for the previous periods/year have been regrouped/reclassified wherever necessary.

Place: Hyderabad
Date: 31st October, 2017



for Divi's Laboratories Limited

[Signature]
Dr. Murali K. Divi
Chairman & Managing Director



Price Waterhouse Chartered Accountants LLP

The Board of Directors
Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/DIVIS/303,
Cyber Hills, Gachibowli,
Hyderabad- 500 032

1. We have reviewed the unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended September 30, 2017 which are included in the accompanying Statement of Standalone Unaudited financial results for the quarter and half year ended September 30, 2017 and the Statement of assets and liabilities as on that date (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. (a) The financial results of the Company for the quarters ended June 30, 2017, September 30, 2016 and half year ended September 30, 2016 prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015, were reviewed by another firm of chartered accountants who issued their unmodified conclusion, vide their reports dated July 22, 2017 and November 12, 2016 respectively.

(b) The financial statements of the Company for the year ended March 31, 2017 was audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated May 26, 2017.

Our conclusion is not qualified in respect of these matters.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: FRN 012754N/N500016



Sunit Kumar Basu
Partner
Membership Number: 55000

Place: Hyderabad
Date: October 31, 2017

Price Waterhouse Chartered Accountants LLP, Plot No. 77/A, 8-2-624/A/1, 3rd Floor, Road No. 10, Banjara Hills
Hyderabad - 500 034
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED

CIN No.L24110TG1990PLC011854

1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli

Hyderabad – 500 032 Telangana, India

Phone: 91-40-23786300 email: kishore@divislabs.com

Press Release dated 31st October, 2017

Divi's Labs earns a total revenue of ₹. 924 crores for Q2 of FY18

Divi's Laboratories has earned a total revenue of ₹. 924 crores for quarter ended 30th September, 2017 as against a total revenue of ₹. 1026 crores in the corresponding quarter of the previous year. Profit after Tax (PAT), before other comprehensive income, for the current quarter came to ₹. 207 crores as against a PAT of ₹. 224 crores for the corresponding quarter of last year.

Forex gain for the quarter amounted to ₹. 11 crores as against a loss of ₹. 11 crore during the corresponding quarter of last year.

Staff cost for the corresponding previous quarter included the one-time ex-gratia of ₹. 79 crores to employees of the company on the occasion of completion of 25 years' formation of the company.

For the half-year ended 30th September, 2017, the company earned a total income of ₹. 1775 crores as against a total income of ₹. 2059 crores during the previous half-year. PAT for the current half-year came to ₹. 383 crores as against ₹. 526 crores for the previous half-year. Results for the previous half-year included the one-time ex-gratia paid to employees.

Forex gain for the current half-year amounted to ₹.18 crores as against a loss of ₹.11 crores during the corresponding period last year.

Revenue for the corresponding previous quarters ended 30th June, 2017 and 30th September, 2016, the half-year ended 30th September, 2016 and the year ended 31st March, 2017 were reported inclusive of Excise Duty. The Government of India has implemented Goods and Services Tax (GST) effective 1st July, 2017 replacing excise duty, service tax and other indirect taxes. Accordingly, as per Ind AS 18, Revenue for the quarter ended 30th September, 2017 is reported net of GST. Had the previously



reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹. in Lakhs)				
	Quarter ended		Half-year ended	
	30.09.2017	30.09.2016	30.09.2017	30.09.2016
Revenue from operations (net of excise duty)	88752	99418	170015	200226

Revenue during the current half-year has been impacted due to the Import Alert issued by US-FDA and the time required for setting up protocols and procedures for release of export shipments as stipulated in the Import Alert by the US-FDA. This has since been established and shipments for the exempted products are being done as per the protocols.

Update on Regulatory Inspections

The company's Unit-II at Visakhapatnam, Andhra Pradesh was inspected by HPRA (Ireland) and JAZMP (Slovenia) from 31st July, 2017 to 4th August, 2017 and the inspection concluded successfully with no critical observations.

The company's Unit-II has also been inspected by the US-FDA from 11th September 2017 to 19th September 2017. This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations. All previous observations have been confirmed as completed and resolved. On completion of the current inspection, the Investigators of US-FDA have issued a Form-483 with 6 observations and the company filed its response to the same within the stipulated time.

